Renalytix Plc
RENX.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.05 | 0.01 | 0.15 |
| FCF Yield | -49.66% | -33.92% | -54.89% | -12.52% |
| EV / EBITDA | -1.61 | -4.63 | -3.31 | -7.18 |
| Quality | ||||
| ROIC | -50.22% | 133.55% | -811.31% | 362.65% |
| Gross Margin | 54.60% | 19.16% | 6.14% | -12.34% |
| Cash Conversion Ratio | 1.67 | 0.81 | 1.11 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.57% | -12.05% | -8.32% | -5.25% |
| Free Cash Flow Growth | -69.37% | 50.99% | -60.88% | 38.57% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | -1.82 | -0.71 | -0.78 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,075.77 | -1,037.94 | -315.88 | -674.72 |